# Ivermectin.
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Final rule, technical amendment.
**SUMMARY:**
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during August 2014. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a change of sponsorship of two NADAs and one ANADA, and to reflect a revised food safety warning.
**DATES:**
This rule is effective October 28, 2014.
**FOR FURTHER INFORMATION CONTACT:**
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, *[email protected].*
**SUPPLEMENTARY INFORMATION:**
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during August 2014, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: *http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.* Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: *http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm.*
In addition, Macleod Pharmaceuticals, Inc., 2600 Canton Ct., Fort Collins, CO 80525 has transferred ownership of, and all rights and interest in ANADA 200-033 for UNIPRIM (trimethoprim and sulfadiazine) Powder to Neogen Corp. (Neogen), 944 Nandino Blvd., Lexington, KY 40511. In 2004, Hess & Clark, Inc., transferred ownership of, and all rights and interest in NADA 011-154 for NFZ Puffer (nitrofurazone soluble powder) and NADA 140-851 for NFZ Wound Dressing (nitrofurazone ointment) to Neogen. At this time, the regulations are being amended to reflect these transfers.
Following these changes of sponsorship, Macleod Pharmaceuticals, Inc., and Hess & Clark, Inc., will no longer be the sponsor of an approved application. Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for these firms.
Also, the animal drug regulations are being amended in 21 CFR 522.690 to revise a human food safety warning for dinoprost tromethamine injectable solution. This amendment is being made to improve the accuracy of the regulations.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
| NADA/ANADA | Sponsor | New animal drug | Action | 21 CFR | FOIA | NEPA Review |
| --- | --- | --- | --- | --- | --- | --- |
| 140-833 | Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640 | IVOMEC Plus (ivermectin and clorsulon) Injection for Cattle | Supplemental approval reducing the preslaughter withdrawal period from 49 days to 21 days | 522.1193 | yes | CE. |
| 141-043 | Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 | SYNOVEX CHOICE (trenbolone and estradiol implant) | Supplemental approval for increased rate of weight gain and improved feed efficiency in heifers fed in confinement for slaughter | 522.2478 | yes | EA/FONSI. |
| 141-342 | Jurox Pty. Ltd., 85 Gardiner Rd., Rutherford, NSW 2320, Australia | ALFAXAN (alfaxalone) Injectable Anesthetic for Dogs and Cats | Supplemental approval adding a label statement that alfaxalone is a Class IV controlled substance | 522.52 | no | CE. |
| 141-348 | Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 | SYNOVEX ONE FEEDLOT (trenbolone and estradiol extended release implant) | Original approval for increased rate of weight gain and improved feed efficiency for up to 200 days in steers and heifers fed in confinement for slaughter | 522.2478 | yes | EA/FONSI. |
| 200-455 | Cross Vetpharm Group Ltd. Broomhill Rd., Tallaght, | TYLOMED-WS (tylosin tartrate) Soluble Powder | Supplemental approval of a change to veterinary prescription (Rx) marketing status to conform with reference (pioneer) product | 520.2640 | no | CE. |
**List of Subjects**
Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.
Animal drugs.
Animal drugs, Foods.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 556 are amended as follows:
**21 CFR Part 510**
**PART 510—NEW ANIMAL DRUGS**
1. The authority citation for 21 CFR part 510 continues to read as follows:
**Authority:**
21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.
**21 CFR Part 510**
2. In § 510.600, in the table in paragraph (c)(1), remove the entries for “Macleod Pharmaceuticals, Inc.” and “Hess & Clark, Inc.” and alphabetically add an entry for “Neogen Corp.”; and in the table in paragraph (c)(2), remove the entries for “058711” and “050749” and numerically add an entry for “059051” to read as follows:
§ 510.600
(c) * * *
(1) * * *
| Firm name and address | Drug labeler code |
| --- | --- |
| | |
| * * * * * * * | |
| Neogen Corp., 944 Nandino Blvd., Lexington, KY 40511 | 059051 |
| | |
| * * * * * * * | |
(2) * * *
| Drug labeler code | Firm name and address |
| --- | --- |
| | |
| * * * * * * * | |
| 059051 | Neogen Corp., 944 Nandino Blvd., Lexington, KY 40511 |
| | |
| * * * * * * * | |
**21 CFR Part 520**
**PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**
3. The authority citation for 21 CFR part 520 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 520**
§ 520.2613
4. In paragraph (b) of § 520.2613, remove “058711” and in its place add “059051”.
5. In § 520.2640, revise paragraphs (b), (d), and (e)(2)(ii) to read as follows:
§ 520.2640
(b) *Sponsors* —(1) No. 000986 for use as in paragraph (e) of this section.
(2) Nos. 016592 and 061623 for use as in paragraphs (e)(1)(i)(A), (e)(1)(ii), (e)(2), (e)(3), and (e)(4) of this section.
(d) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(e) * * *
(2) * * *
(ii) *Indications for use.* For the reduction in severity of effects of infectious sinusitis associated with *Mycoplasma gallisepticum.*
**21 CFR Part 522**
**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**
6. The authority citation for 21 CFR part 522 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
7. In § 522.52, in paragraph (c)(3), add a second sentence to read as follows:
§ 522.52
(c) * * *
(3) * * * Alfaxalone is a Class IV controlled substance.
**21 CFR Part 522**
8. In § 522.690, revise paragraph (d)(1)(iii) to read as follows:
§ 522.690
(d) * * *
(1) * * *
(iii) *Limitations.* Do not use in horses intended for human consumption.
**21 CFR Part 522**
9. In § 522.1193, revise paragraph (e)(3) to read as follows:
§ 522.1193
(e) * * *
(3) *Limitations.* For No. 050604: Do not treat cattle within 21 days of slaughter. For Nos. 055529 and 058005: Do not treat cattle within 49 days of slaughter. Because a withdrawal time in milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.
**21 CFR Part 522**
10. In § 522.2478, revise paragraphs (a), (d)(1)(i) introductory text, (d)(1)(ii) introductory text, and (d)(2); and add paragraphs (d)(1)(iii) and (d)(3) to read as follows:
§ 522.2478
(a) *Specifications* —(1) Each implant consists of:
(i) 8 pellets, each pellet containing 25 milligrams (mg) trenbolone acetate and 3.5 mg estradiol benzoate.
(ii) 4 pellets, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.
(2) Each extended release implant consists of:
(i) 8 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.
(ii) 6 pellets with a porous polymer film coating, each pellet containing 25 mg trenbolone acetate and 3.5 mg estradiol benzoate.
(d) * * *
(1) * * *
(i) For an implant as described in paragraph (a)(1)(i) of this section:
(ii) For an implant as described in paragraph (a)(1)(ii) of this section:
(iii) For an implant as described in paragraph (a)(2)(i) of this section:
(A) *Amount.* 200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant.
(B) *Indications for use.* For increased rate of weight gain and improved feed efficiency for up to 200 days.
(C) *Limitations.* Implant subcutaneously in ear only. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(2) *Heifers fed in confinement for slaughter* —(i) For an implant as described in paragraph (a)(1)(i) of this section:
(A) *Amount.* 200 mg trenbolone acetate and 28 mg estradiol benzoate.
(B) *Indications for use.* For increased rate of weight gain.
(C) *Limitations.* Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(ii) For an implant as described in paragraph (a)(1)(ii) of this section:
(A) *Amount.* 100 mg trenbolone acetate and 14 mg estradiol benzoate.
(B) *Indications for use.* For increased rate of weight gain and improved feed efficiency.
(C) *Limitations.* Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(iii) For an implant as described in paragraph (a)(2)(i) of this section:
(A) *Amount.* 200 mg trenbolone acetate and 28 mg estradiol benzoate in an extended release implant.
(B) *Indications for use.* For increased rate of weight gain and improved feed efficiency for up to 200 days.
(C) *Limitations.* Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(3) *Pasture steers and heifers (slaughter, stocker, and feeder)* —(i) For an implant as described in paragraph (a)(2)(ii) of this section:
(A) *Amount.* 150 mg trenbolone acetate and 21 mg estradiol benzoate in an extended release implant.
(B) *Indications for use.* For increased rate of weight gain for up to 200 days.
(C) *Limitations.* Implant subcutaneously in ear only. Not for use in dairy or beef replacement heifers. Safety and effectiveness have not been established in veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(ii) [Reserved]
**21 CFR Part 524**
**PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS**
11. The authority citation for 21 CFR part 524 continues to read as follows:
**Authority:**
21 U.S.C. 360b.
**21 CFR Part 524**
§ 524.1580a
12. In paragraph (b)(1) of § 524.1580a, remove “Nos. 050749, 054628, 054925, 058005, and 061623” and add in its place “Nos. 054628, 054925, 058005, 059051, and 061623”.
**21 CFR Part 524**
§ 524.1580b
13. In paragraph (b) of § 524.1580b, remove “No. 054628” and in its place add “Nos. 054628 and 059051”.
**21 CFR Part 556**
**PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD**
14. The authority citation for 21 CFR part 556 continues to read as follows:
**Authority:**
21 U.S.C. 342, 360b, 371.
**21 CFR Part 556**
15. In § 556.344, revise paragraphs (a), (b)(1)(i), and (b)(2)(ii); and add paragraph (c) to read as follows:
§ 556.344
(a) *Acceptable Daily Intake (ADI).* The ADI for total residues of ivermectin is 5 micrograms per kilogram of body weight per day.
(b) * * *
(1) * * *
(i) *Cattle.* 1.6 parts per million.
(2) * * *
(ii) *Cattle.* 650 parts per billion.
(c) *Related conditions of use.* See §§ 520.1192, 520.1195, 520.1197, 522.1192, 522.1193, 524.1193, and 558.300 of this chapter.
Dated:
Bernadette Dunham,
Director, Center for Veterinary Medicine.